复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02196 复星医药

未开盘 12-15 16:08:35

22.360

-0.160

-0.71%

最高22.700	最低22.180	成交量456.01万
今开22.700	昨收22.520	日振幅2.31%
总市值594.55亿	流通市值120.96亿	总股本26.59亿
成交额1.02亿	换手率0.84%	流通股本5.41亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"复星医药","latestPrice":22.36,"timestamp":1765786115004,"preClose":22.52,"halted":0,"volume":4560119,"delay":0,"floatShares":540971500,"shares":2659000000,"eps":1.1460361979874392,"marketStatus":"未开盘","change":-0.16,"latestTime":"12-15 16:08:35","open":22.7,"high":22.7,"low":22.18,"amount":102402525,"amplitude":0.023091,"askPrice":22.4,"askSize":7500,"bidPrice":22.36,"bidSize":5000,"shortable":3,"etf":0,"ttmEps":1.367654698279284,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765848600000},"marketStatusCode":0,"adr":0,"listingDate":1351526400000,"exchange":"SEHK","adjPreClose":22.52,"dividendRate":0.015657,"openAndCloseTimeList":[[1765762200000,1765771200000],[1765774800000,1765785600000]],"volumeRatio":0.762856,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"复星医药","latestPrice":27.93,"timestamp":1765782000000,"preClose":28.28,"halted":0,"volume":14609800,"delay":0,"premium":"-27.54"}},"requestUrl":"/m/hq/s/02196/wiki","defaultTab":"wiki","newsList":[{"id":"2591640875","title":"港股公告掘金 | 果下科技明日上市 公开发售获1890.73倍认购 三大航11月旅客周转量均同比升逾一成","url":"https://stock-news.laohu8.com/highlight/detail?id=2591640875","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591640875?lang=zh_cn&edition=full","pubTime":"2025-12-15 23:03","pubTimestamp":1765811013,"startTime":"0","endTime":"0","summary":"【新股上市】果下科技(02655)：香港公开发售获1890.73倍认购 每股发售价20.1港元轻松健康(02661)12月15日至12月18日招股 预计12月23日上市翰思艾泰-B(03378)12月15日至12月18日招股 预计12月23日上市诺比侃(02635)12月15日至12月18日招股 预计12月23日上市【重大事项】洛阳钼业(03993)拟10.15亿美元收购巴西三大金矿资产中伟新材(","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381850.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0140636845.USD","LU0345769128.USD","LU1242518857.USD","03993","LU1196710195.USD","HTCD.SI","LU0650527681.SGD","TCHmain","LU2097828714.EUR","LU0871576103.HKD","LU0786609619.USD","SG9999001069.SGD","LU0011963245.USD","LU0417516738.SGD","SG9999017495.SGD","LU0828238088.HKD","02579","LU0326948709.USD","LU0348788117.USD","LU1769817179.HKD","IE0008368742.USD","LU0261947096.USD","IE0008369823.USD","LU0345775950.USD","LU0985320562.USD","LU0594300419.USD","LU2237443895.HKD","LU0456842615.SGD","LU0541502299.USD","02196","LU0175139822.USD","LU2226246903.HKD","LU0608807946.USD","LU0449509016.USD","LU2778985437.USD","LU0051755006.USD","LU0823038988.USD","LU0898667661.SGD","02655","LU0396098781.USD","HK0000306701.USD","LU0181495838.USD","LU0791591158.USD","LU1046422090.SGD","LU2045819591.USD","BK1615","BK1521","LU1282649141.HKD","LU0572939691.SGD"],"gpt_icon":1},{"id":"2591642540","title":"复星医药14亿入局阿尔茨海默病 缘何选择押注绿谷“九期一”？","url":"https://stock-news.laohu8.com/highlight/detail?id=2591642540","media":"21世纪经济报道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591642540?lang=zh_cn&edition=full","pubTime":"2025-12-15 22:14","pubTimestamp":1765808084,"startTime":"0","endTime":"0","summary":"近日，阿尔茨海默病药物赛道异常热闹。在两款近年来最具突破性的阿尔茨海默病对因治疗药物——仑卡奈单抗注射液和多奈单抗注射液双双入选我国首版《商业健康保险创新药品目录》后，争议与机遇并存的国产阿尔茨海默病药物甘露特钠，在面临停产、换证危机之际，迎来了中国医药巨头复星医药的入局。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512153592045515.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512153592045515.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","02196","BK0183","BK0187","BK0188","BK1191","BK1593","BK0028","BK0060","600196","BK1515","BK0012","BK0196","BK0175","BK0096"],"gpt_icon":0},{"id":"2591648625","title":"争议药物\"九期一\"获新生？复星医药14亿元收购绿谷医药重启临床与商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=2591648625","media":"蓝鲸财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591648625?lang=zh_cn&edition=full","pubTime":"2025-12-15 18:51","pubTimestamp":1765795877,"startTime":"0","endTime":"0","summary":"此次收购案后，复星医药方面表示，甘露特钠胶囊重新开展商业化生产和销售前，还需补充完成目前尚在开展的上市后确证性临床试验并获得国家药品审评部门批准。本次收购完成后，复星医药将携绿谷医药团队在药品审评部门的指导下，有序严谨推进上市后确证性临床试验，以期尽快实现获批；并适时开展相关适应症的国际多中心临床试验，惠及更多阿尔茨海默病患者。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1765795546434638047","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK0183","BK0175","BK0188","BK1191","BK1515","BK0028","BK0187","BK0196","BK0060","BK1593","BK0012","600196","09939","BK1161","02196","BK0096","BK1574","BK0239","159938"],"gpt_icon":1},{"id":"2591612068","title":"复星医药：控股子公司拟出资14.12亿元投资绿谷医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2591612068","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591612068?lang=zh_cn&edition=full","pubTime":"2025-12-15 17:43","pubTimestamp":1765791813,"startTime":"0","endTime":"0","summary":"每经AI快讯，12月15日，复星医药(600196.SH)公告称，公司控股子公司复星医药产业拟出资共计14.12亿元投资绿谷医药，包括受让部分股权和认缴新增注册资本。完成后，公司将通过复星医药产业及SPV合计持有绿谷医药53%的股权。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512153591807093.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512153591807093.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1593","BK1191","BK0012","BK0096","BK1574","BK1515","09939","BK0060","BK0188","BK0175","BK0239","BK0196","600196","BK0183","BK0187","BK0028","02196","159938","BK1161"],"gpt_icon":0},{"id":"2591865967","title":"复星医药控股子公司酮洛芬贴剂获准开展III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2591865967","media":"中金财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591865967?lang=zh_cn&edition=full","pubTime":"2025-12-14 08:13","pubTimestamp":1765671185,"startTime":"0","endTime":"0","summary":"中访网数据 上海复星医药(集团)股份有限公司于2025年12月12日发布公告，其控股子公司上海朝晖药业有限公司研发的酮洛芬贴剂，已获得国家药品监督管理局批准，将在中国境内开展III期临床试验。　　该事件的影响范围主要集中于复星医药集团及其控股子公司朝晖药业的研发管线推进，以及未来潜在的非甾体抗炎药外用贴剂市场。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251214/31864526.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0196","600196","BK0239","BK0187","BK0012","BK0060","BK0188","BK1191","BK4134","BK0096","BK0183","III","02196","BK1515","BK0175","BK0028","BK1593"],"gpt_icon":0},{"id":"2591594657","title":"30亿+首仿，复星医药“明星”抗凝药新剂型获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2591594657","media":"北京药研汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591594657?lang=zh_cn&edition=full","pubTime":"2025-12-14 08:01","pubTimestamp":1765670477,"startTime":"0","endTime":"0","summary":"在国内，拜耳的利伐沙班片于2009年3月获批上市，商品名为拜瑞妥。利伐沙班是目前中国唯一拥有儿童VET治疗及预防复发适应症的抗凝药物。目前，利伐沙班拥有片剂、颗粒剂、口崩片及干混悬剂4种制剂获批上市。截至目前为止，利伐沙班干混悬剂原研尚未在国内上市。此次，桂林南药申报的利伐沙班干混悬剂成功获批上市，为本品首仿+首家过评。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214081218a69f8716&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214081218a69f8716&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1515","02196","BK1593"],"gpt_icon":0},{"id":"2591865613","title":"辉瑞斥资“20亿美元”锁定“复星医药”口服GLP-1减重药全球权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2591865613","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591865613?lang=zh_cn&edition=full","pubTime":"2025-12-14 00:01","pubTimestamp":1765641660,"startTime":"0","endTime":"0","summary":"12月9日晚，复星医药公告其控股子公司与辉瑞签订《许可协议》，将自主研发的口服GLP-1R激动剂YP05002的全球独家开发、生产及商业化权利授予辉瑞，交易总价值最高达20.85亿美元，创国产口服GLP-1出海规模新高。YP05002是复星医药自主研发的口服小分子GLP-1R激动剂，主要瞄准代谢领域相关疾病，已在澳大利亚进入I期临床试验阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214013031a447bcc8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214013031a447bcc8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02196","BK1191","BK1515","BK1593"],"gpt_icon":0},{"id":"2591632904","title":"英伟达连续布局13家企业，AI制药3个方向梳理（附列表）","url":"https://stock-news.laohu8.com/highlight/detail?id=2591632904","media":"投研大叔","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591632904?lang=zh_cn&edition=full","pubTime":"2025-12-13 19:40","pubTimestamp":1765626014,"startTime":"0","endTime":"0","summary":"今天介绍下AI制药，英伟达在过去2年投资13家AI药企，推出BioNeMo生物分子AI框架已经覆盖上百家药企，英硅智能ISM001-055进入临床III期，成为首个跨越临床II期的AI药物，从之前的布局到如今逐渐突破，商业价值正在逐渐被验证。从大叔个人来看，还有一些罕见病，由于患者少，研发不划算，而AI能快速低成本设计药物，让更多罕见病有药可治。近期热门文章HW组建医疗卫生军团，AI医疗爆发！","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251213194757a4470c58&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251213194757a4470c58&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NVD2.UK","02196","NVDD","LU2860962120.EUR","03759","LU0157215616.USD","LU0096362180.USD","SNVD.UK","LU2505996509.AUD","LU2505996681.GBP","LU2191332357.HKD","LU0158827948.USD","LU2237438978.USD","NVDY","LU1496350171.SGD","NVDA","IE0034235188.USD","LU1914381329.SGD","06821","LU0274383776.USD","IE00BDCRKT87.USD","NVD","SGXZ81514606.USD","LU1839511570.USD","LU2602419157.SGD","NVIW.SI","SG9999004303.SGD","LU2089284900.SGD","IE000ITXATA3.USD","LU1145028129.USD","LU1280957306.USD","2NVD.UK","LU0719512351.SGD","LU1988902786.USD","02359","LU2463028550.USD","LU2249611893.SGD","LU2473716301.USD","LU0320765059.SGD","NVDS","NVDX","LU2065171311.SGD","02228","NVD3.UK","NVDU","01093","IE000YTNTUN2.SGD","LU0444973449.USD","3NVD.UK","LU0308772762.SGD","LU1642822529.SGD","IE00BJJMRY28.SGD","LU2592432038.USD","06127","LU2420271590.USD","NVDS.UK"],"gpt_icon":1},{"id":"2591630618","title":"复星医药：再次牵手MNC 创新转型持续推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2591630618","media":"天风证券","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591630618?lang=zh_cn&edition=full","pubTime":"2025-12-13 00:00","pubTimestamp":1765555200,"startTime":"0","endTime":"0","summary":"事件12 月9 日，复星医药公告，其控股子公司药友制药与辉瑞签订《许可协议》，授予辉瑞口服小分子GLP-1R 激动剂YP05002 及含有该活性成分的产品在全球范围内独家开发、使用、生产及商业化权利。2025 年已完成3 笔license-out 交易，创新转型持续推进复星医药向Sitala 授予FXS6837 全球权益，取得首付款2500 万美元，潜在总金额6.70 亿美元。本次与辉瑞的交易，是复星医药2025 年完成的第三笔交易，且交易对手方的体量和交易规模大幅度提升，再次证实公司创新转型的决心及成果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251213141623a446516e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251213141623a446516e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02196","BK1191","BK1593","BK1515"],"gpt_icon":0},{"id":"2590504257","title":"复星医药（600196）披露控股子公司药品注册申请获受理，12月12日股价下跌0.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590504257","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590504257?lang=zh_cn&edition=full","pubTime":"2025-12-12 22:07","pubTimestamp":1765548445,"startTime":"0","endTime":"0","summary":"截至2025年12月12日收盘，复星医药报收于28.28元，较前一交易日下跌0.91%，最新总市值为755.2亿元。该股当日开盘28.5元，最高28.59元，最低28.01元，成交额达5.67亿元，换手率为0.95%。近日，上海复星医药（集团）股份有限公司发布公告称，其控股子公司复宏汉霖就斯鲁利单抗注射液新增适应症的药品注册申请获国家药监局受理，并纳入优先审评程序。本次注册申请获受理不会对本集团现阶段业绩产生重大影响，后续仍需获得药品注册批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121200040751.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK1593","BK0012","BK0028","BK0187","BK0239","BK0188","600196","BK0183","BK1515","BK0196","02196","BK0096","BK0175","BK1191"],"gpt_icon":0},{"id":"2590572449","title":"复星医药(600196.SH)：斯鲁利单抗注射液新增适应症药品注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2590572449","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590572449?lang=zh_cn&edition=full","pubTime":"2025-12-12 17:38","pubTimestamp":1765532312,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 发布公告，近日，公司控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司就斯鲁利单抗注射液新增适应症的药品注册申请获国家药品监督管理局受理，并已获纳入优先审评程序。该药品为集团自主研发的创新型抗PD-1单抗。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380944.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0183","BK0239","BK0060","600196","02196","BK0187","BK1593","BK0175","BK0096","BK1515","BK0188","BK0012","BK0196","BK0028","BK1191"],"gpt_icon":0},{"id":"2590506572","title":"复星医药(600196.SH)：酮洛芬贴剂获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2590506572","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590506572?lang=zh_cn&edition=full","pubTime":"2025-12-12 17:32","pubTimestamp":1765531926,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(600196.SH)发布公告，近日，公司控股子公司上海朝晖药业有限公司(以下简称“朝晖药业”)收到国家药品监督管理局(以下简称“国家药监局”)关于同意酮洛芬贴剂(以下简称“该药品”)开展临床试验的批准。朝晖药业拟于条件具备后于中国境内1开展该药品的Ⅲ期临床试验。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380936.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1191","BK0175","BK0012","BK1515","BK0188","BK0239","600196","BK0060","BK0028","BK1593","02196","BK0196","BK0183","BK0096","BK0187"],"gpt_icon":0},{"id":"2590552136","title":"留给国产“口服GLP-1”的机会不多了","url":"https://stock-news.laohu8.com/highlight/detail?id=2590552136","media":"医曜","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590552136?lang=zh_cn&edition=full","pubTime":"2025-12-12 07:29","pubTimestamp":1765495759,"startTime":"0","endTime":"0","summary":"在终止口服GLP-1核心管线danuglipron研发的八个月后，辉瑞再次出手引入“口服GLP-1”资产。这一“反常规”选择的潜台词，恰恰折射出其他国产口服GLP-1药物的尴尬处境。如今，辉瑞、默沙东、阿斯利康等跨国药企均已通过BD合作完成口服GLP-1领域的核心布局，留给其他国产口服GLP-1产品的市场机会已愈发有限。01辉瑞之殇在“口服GLP-1”这一热门赛道，辉瑞一度频下重注。早在2023年6月，辉瑞便因安全性问题，终止了首款口服小分子GLP-1药物lotiglipron的研发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512120737099538a06e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512120737099538a06e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","BK1191","BK1515","02196"],"gpt_icon":0},{"id":"2590752130","title":"每日卖空追踪 | 复星医药 12月11日卖空量成交17.8万股，卖空比例为2.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590752130","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590752130?lang=zh_cn&edition=full","pubTime":"2025-12-11 16:30","pubTimestamp":1765441827,"startTime":"0","endTime":"0","summary":"复星医药北京时间12月11日，跌0.09%，卖空量成交17.8万股，较上一交易日减少83.51%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025121116351295375d4c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025121116351295375d4c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1191","BK1593","02196"],"gpt_icon":0},{"id":"2590535521","title":"复星医药旗下生物科技公司增资至22.3亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2590535521","media":"21世纪经济报道","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590535521?lang=zh_cn&edition=full","pubTime":"2025-12-11 15:23","pubTimestamp":1765437780,"startTime":"0","endTime":"0","summary":"南方财经12月11日电，天眼查App显示，近日，复星凯瑞 生物科技有限公司发生工商变更，新增深圳市鹏复生物医药产业私募股权投资基金合伙企业、深圳市坪山区引导基金投资有限公司、上海复瑞益企业咨询管理合伙企业为股东，同时，注册资本由约19.2亿人民币增至约22.3亿人民币，增幅约16%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211152419a441d2cb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211152419a441d2cb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","02196","BK1515","BK1593"],"gpt_icon":0},{"id":"2590307040","title":"复星医药子公司桂林南药膦甲酸钠注射液注册申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2590307040","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590307040?lang=zh_cn&edition=full","pubTime":"2025-12-10 16:55","pubTimestamp":1765356926,"startTime":"0","endTime":"0","summary":"12月10日，复星医药（600196/02196）发布公告，控股子公司桂林南药股份有限公司的膦甲酸钠注射液药品注册申请已获国家药品监督管理局批准。该药品适应症包括用于治疗艾滋病患者巨细胞病毒性视网膜炎和免疫功能损害患者耐阿昔洛韦单纯疱疹病毒性皮肤粘膜感染。截至2025年11月，公司针对该药品的研发累计投入约为498万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512103587726156.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02196","BK0012","BK0188","600196","BK0060","BK0096","BK1515","BK0183","BK1593","BK0028","BK0239","BK1191","BK0187","BK0196","BK0175"],"gpt_icon":0},{"id":"2590309455","title":"群益证券：维持复星医药(02196)“买进”评级 目标价26.5港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2590309455","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590309455?lang=zh_cn&edition=full","pubTime":"2025-12-10 15:24","pubTimestamp":1765351440,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，群益证券发布研报称，为反映复星医药大额首付款增厚利润，该行上调盈利预测。该行预计公司2025-2027年分别实现净利润33.2亿元、46.8亿元、47.7亿元，YOY分别+19.8%、+40.8%、+19.1%，EPS分别为1.2元、1.8元、1.8元，对应H股PE分别为16X/11X/11X,H股估值偏低，该行看好其长期发展，维持H股“买进”的投资评级，目标价26.5港元。此外，基于许可产品的年度净销售额达成情况，由辉瑞向药友制药支付至多15.85亿美元的销售里程碑款项。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379822.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["161027","600196","02196"],"gpt_icon":0},{"id":"2590937964","title":"复星医药A股和H股分别上涨近4%和近6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590937964","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590937964?lang=zh_cn&edition=full","pubTime":"2025-12-10 09:56","pubTimestamp":1765331812,"startTime":"0","endTime":"0","summary":"复星医药A股和H股分别上涨近4%和近6%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512103587445239.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512103587445239.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0187","02196","BK0096","BK0012","BK0060","159982","BK0175","600196","BK0188","BK1593","BK0183","BK0196","BK1515","399300","BK0028","BK1191","BK0239"],"gpt_icon":0},{"id":"1119764520","title":"复星医药盘初涨超6%！药友制药授予辉瑞GLP-1R激动剂全球独家研发及商业化许可","url":"https://stock-news.laohu8.com/highlight/detail?id=1119764520","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119764520?lang=zh_cn&edition=full","pubTime":"2025-12-10 09:38","pubTimestamp":1765330699,"startTime":"0","endTime":"0","summary":"药友制药授予$辉瑞$GLP-1R激动剂全球独家研发及商业化许可。复星医药发布公告，2025年12月9日，公司控股子公司药友制药、复星医药产业与辉瑞共同签订《许可协议》，由药友制药就口服小分子胰高血糖素样肽-1受体激动剂及含有该活性成分的产品授予辉瑞于许可区域及领域独家开发、使用、生产及商业化权利；就本次许可，药友制药将有权依约获得不可退还的首付款1.5亿美元及基于许可产品临床、商业化进展获得开发里程碑付款至多3.5亿美元。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"6692cc092fbadfcafce950a9c4d79e01","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"复星医药盘初涨超6%！药友制药授予辉瑞GLP-1R激动剂全球独家研发及商业化许可","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196"],"gpt_icon":1},{"id":"2590345800","title":"复星医药(600196.SH)：HLX22联合注射用HLX87获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2590345800","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590345800?lang=zh_cn&edition=full","pubTime":"2025-12-09 20:09","pubTimestamp":1765282177,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(600196.SH)发布公告，近日，公司控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司(以下合称“复宏汉霖”)收到国家药品监督管理局关于同意HLX22(即重组人源化抗HER2单克隆抗体注射液)联合注射用HLX87(即靶向HER2抗体偶联药物)于中国境内开展如下临床试验的批准：(1)用于HER2阳性乳腺癌(BC)一线治疗的Ⅱ/Ⅲ期临床试验;(2)用于HER2阳性乳腺癌新辅助治疗(BC neo)的Ⅱ/Ⅲ期临床试验。复宏汉霖拟于条件具备后于中国境内开展上述相关临床研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379535.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02196","BK0175","BK1191","BK0188","600196","BK0028","BK0196","BK0239","BK1593","BK0183","BK0012","BK1515","BK0060","BK0187","BK0096"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fosunpharma.com","stockEarnings":[{"period":"1week","weight":0.0508},{"period":"1month","weight":-0.0337},{"period":"3month","weight":-0.2082},{"period":"6month","weight":0.4338},{"period":"1year","weight":0.5942},{"period":"ytd","weight":0.6146}],"compareEarnings":[{"period":"1week","weight":-0.0053},{"period":"1month","weight":-0.0533},{"period":"3month","weight":-0.0306},{"period":"6month","weight":0.0809},{"period":"1year","weight":0.2833},{"period":"ytd","weight":0.2776}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海复星医药（集团）股份有限公司是一家主要从事医药产品研发、制造与销售的中国公司。该公司经营五个分部。制药分部主要从事创新药、成熟医药产品制造和疫苗业务。医疗器械与医学诊断分部主要从事分子诊断、免疫诊断、微生物诊断等医疗美容器械的制造和销售。医疗健康服务分部主要从事线上线下一体化医疗服务平台的经营。医药分销和零售分部主要从事医药产品的批发零售。其他分部从事其他医药相关业务。该公司的产品主要用于肿瘤、免疫、中枢神经等治疗领域。","yearOnYearQuotes":[{"month":1,"riseRate":0.384615,"avgChangeRate":-0.051338},{"month":2,"riseRate":0.769231,"avgChangeRate":0.040467},{"month":3,"riseRate":0.615385,"avgChangeRate":0.048431},{"month":4,"riseRate":0.384615,"avgChangeRate":0.03076},{"month":5,"riseRate":0.461538,"avgChangeRate":0.035265},{"month":6,"riseRate":0.461538,"avgChangeRate":-0.026545},{"month":7,"riseRate":0.615385,"avgChangeRate":0.027595},{"month":8,"riseRate":0.307692,"avgChangeRate":-0.041651},{"month":9,"riseRate":0.461538,"avgChangeRate":0.011609},{"month":10,"riseRate":0.461538,"avgChangeRate":0.020359},{"month":11,"riseRate":0.428571,"avgChangeRate":0.034495},{"month":12,"riseRate":0.5,"avgChangeRate":0.02469}],"exchange":"SEHK","name":"复星医药","nameEN":"FOSUN PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复星医药,02196,复星医药股票,复星医药股票老虎,复星医药股票老虎国际,复星医药行情,复星医药股票行情,复星医药股价,复星医药股市,复星医药股票价格,复星医药股票交易,复星医药股票购买,复星医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}